Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Takeda
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Participant is diagnosed with HAE-C1INH-Type 1 or HAE-C1INH-Type 2 and initiated on long-term prophylaxis (LTP) with Takhzyro® (lanadelumab).
2. Participant is aged greater than or equal to (\>=) 12 years at the time of Takhzyro® initiation.
3. Participant has received at least 6 months of continuous treatment with Takhzyro® before data abstraction.
You may not be if
1. Participants who have normal C1INH function or HAE-nC1INH (formerly type III HAE).
2. Participants who discontinued Takhzyro® before completing 6 months of treatment.
3. Participants with insufficient or incomplete medical records which prevent the assessment of baseline HAE-AS at the time of Takhzyro® initiation, as well as 6 months HAE-AS after treatment initiation.
4. Participants who are participating in an interventional clinical trial involving other HAE-C1INH treatments during the observation period.